EMA won’t clear chloroquine for COVID-19 without trial dataThe European drugs regulator has stopped short of granting widespread use of the drug chloroquine against COVID-19, days Share XEMA won’t clear chloroquine for COVID-19 without trial datahttps://pharmaphorum.com/news/ema-refuses-to-clear-chloroquine-for-covid-19-without-data/
CHMP backs safety of anticoagulants after real-world studyThe EMA’s human drugs advisory committee has said that no change is needed to the use of direct Share XCHMP backs safety of anticoagulants after real-world studyhttps://pharmaphorum.com/news/chmp-backs-safety-of-anticoagulants-after-real-world-study/
Novartis closes on EU approval for SMA gene therapy ZolgensmaNovartis is on the final straight to approval of its spinal muscular atrophy (SMA) gene therapy Zolgensma in Share XNovartis closes on EU approval for SMA gene therapy Zolgensmahttps://pharmaphorum.com/news/novartis-closes-on-eu-approval-for-sma-gene-therapy-zolgensma/
Pfizer’s EU Vyndaqel okay ‘sets up $1.5bn sales next year’Pfizer’s Vyndaqel has become the first drug to be approved for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in Europe, Share XPfizer’s EU Vyndaqel okay ‘sets up $1.5bn sales next year’https://pharmaphorum.com/news/pfizers-eu-vyndaqel-okay-sets-up-1-5bn-sales-next-year/
Dutch biotech sector feel benefits of EMA move, says industry leaderThe Netherlands’ biotech sector has already seen an upswing following the relocation of the European Medicines Agency (EMA) Share XDutch biotech sector feel benefits of EMA move, says industry leaderhttps://pharmaphorum.com/news/dutch-biotech-feeling-benefits-of-ema-relocation-says-industry-leader/
EMA proposes 10 recommendations to unlock potential of big dataEuropean regulators have proposed ten recommendations that aim to unlock the potential of big data for public health Share XEMA proposes 10 recommendations to unlock potential of big datahttps://pharmaphorum.com/news/ema-proposes-10-recommendations-to-unlock-potential-of-big-data/
EMA counts the cost of Brexit in lost staff and narrower workloadThe EMA’s forced move from London to Amsterdam in the wake of the UK’s decision to leave the Share XEMA counts the cost of Brexit in lost staff and narrower workloadhttps://pharmaphorum.com/news/ema-counts-the-cost-of-brexit-in-lost-staff-and-narrower-workload/
Merck’s last-resort antibiotic Recarbrio nears EU approvalMerck & Co/MSD’s three-drug antibiotic Recarbrio has been recommended for approval in Europe for Gram-negative infections, but should Share XMerck’s last-resort antibiotic Recarbrio nears EU approvalhttps://pharmaphorum.com/news/mercks-last-resort-antibiotic-recarbrio-nears-eu-approval/
EMA resolves dispute over pricey Canary Wharf tenancyAfter months of wrangling, the EMA finally has a solution to the £500 million financial liability it has Share XEMA resolves dispute over pricey Canary Wharf tenancyhttps://pharmaphorum.com/news/ema-resolves-dispute-over-pricey-canary-wharf-tenancy/
